| 11.01 0.27 (2.51%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.59 |
1-year : | 17.05 |
| Resists | First : | 12.5 |
Second : | 14.59 |
| Pivot price | 9.41  |
|||
| Supports | First : | 8.97 |
Second : | 6.8 |
| MAs | MA(5) : | 11.01 |
MA(20) : | 9.28 |
| MA(100) : | 10.34 |
MA(250) : | 15.07 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.3 |
D(3) : | 74.9 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 82 | Low : | 6.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RDHL ] has closed below upper band by 18.0%. Bollinger Bands are 33.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.66 - 11.71 | 11.71 - 11.77 |
| Low: | 10.62 - 10.68 | 10.68 - 10.74 |
| Close: | 10.92 - 11.01 | 11.01 - 11.1 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Tue, 10 Sep 2024
This Is Why RedHill Biopharma Ltd.'s (NASDAQ:RDHL) CEO Compensation Looks Appropriate - Simply Wall St
Mon, 09 Sep 2024
Redhill Biopharma Ltd (RDHL) Trading 9.81% Higher on Sep 9 - GuruFocus.com
Thu, 05 Sep 2024
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - StockTitan
Tue, 20 Aug 2024
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
Mon, 19 Aug 2024
Why Is RedHill Biopharma Stock Trading Higher Today? - Redhill Biopharma (NASDAQ:RDHL) - Benzinga
Fri, 16 Aug 2024
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.109e+010 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.094e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -328.5 % |
| Return on Assets (ttm) | -44.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 3.71e+006 % |
| Gross Profit (p.s.) | -7.74 |
| Sales Per Share | 193.08 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -302.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.05 |
| Price to Cash Flow | 808.13 |
| Dividend | 0 |
| Forward Dividend | 120470 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|